T. Rowe Price Associates’s PharmaCyte Biotech PMCB Stock Holding History

T. Rowe Price Associates’s Portfolio PMCB Stock Details PMCB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-25,600	Closed	-$75K	–	2928
2023 Q1	$75K	Sell	25,600 -10,800	-30%	-$31.7K	﹤0.01%	2735
2022 Q4	$106K	Sell	36,400 -10,600	-23%	-$30.4K	﹤0.01%	2708
2022 Q3	$113K	Sell	47,000 -15,000	-24%	-$37.9K	﹤0.01%	2702
2022 Q2	$140K	Sell	62,000 -16,100	-21%	-$35.2K	﹤0.01%	2686
2022 Q1	$180K	Hold	78,100	–	–	﹤0.01%	2740
2021 Q4	$195K	Sell	78,100 -55,500	-42%	-$153K	﹤0.01%	2766
2021 Q3	$424K	Buy	+133,600	New	+$470K	﹤0.01%	2449

Other funds holding PMCB

Ayrton Capital Westport, Connecticut $14.7M AUM 12.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KPF

K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

EPM

Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

T. Rowe Price Associates's PMCB Position: Q2 2023 in Review

T. Rowe Price Associates sold out of PharmaCyte Biotech (PMCB) in Q2 2023, closing a stake of 25,600 shares — an estimated $75K sold.

T. Rowe Price Associates first reported a position in PMCB in Q3 2021 and held it in 7 quarters. The position peaked at $424K in Q3 2021. 29 funds tracked by Wall St. Rank hold PMCB as of Q2 2023.

T. Rowe Price Associates reported no remaining PharmaCyte Biotech position as of Q2 2023 after selling out during the quarter.
T. Rowe Price Associates sold 25,600 PharmaCyte Biotech shares in Q2 2023, an estimated $75K.
T. Rowe Price Associates first reported a position in PharmaCyte Biotech in Q3 2021 and held it in 7 quarters.
T. Rowe Price Associates's PharmaCyte Biotech position peaked at $424K in Q3 2021.
29 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q2 2023.

Based on T. Rowe Price Associates's 13F filing for Q2 2023, filed 14 Aug 2023.